Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts) Meeting Abstract


Authors: McArthur, G. A.; Ribas, A.; Chapman, P. B.; Flaherty, K. T.; Kim, K. B.; Puzanov, I.; Nathanson, K. L.; Lee, R. J.; Koehler, A.; Spleiss, O.; Bollag, G.; Wu, W.; Trunzer, K.; Sosman, J. A.
Abstract Title: Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts)
Meeting Title: 47th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title: Journal of Clinical Oncology
Volume: 29
Issue: 15 Suppl.
Meeting Dates: 2011 Jun 3-7
Meeting Location: Chicago, IL
ISSN: 0732-183X
Publisher: American Society of Clinical Oncology  
Date Published: 2011-05-20
Language: English
ACCESSION: WOS:000208880302365
DOI: 10.1200/jco.2011.29.15_suppl.8502
PROVIDER: wos
Notes: Meeting Abstract: 8502 -- Source: Wos
Altmetric Score
MSK Authors
  1. Paul Chapman
    252 Chapman